Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

According to recent analyses, there was a modest yet significant improvement in median
survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North …

Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …

Objective Patients with etoposide/platinum-refractory extensive disease (ED) small-cell lung
cancer (SCLC) have a dismal prognosis. We aimed to evaluate the efficacy and safety of …

This study examined the activity and safety of amrubicin monotherapy among relapsed small-
cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus …

Introduction Traditionally, relapsed SCLC has been classified as “sensitive” or “refractory” on
the basis of cutoff values (60 or 90 d) for the duration between the last chemotherapy and …

Currently, amrubicin is permitted for relapsed small-cell lung carcinoma (SCLC) only in
Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied …

Although small-cell lung cancer (SCLC) generally shows an excellent response to initial
chemotherapy, most patients finally relapse and salvage chemotherapy is considered …

Simple Summary Small cell lung cancer is a subtype of lung cancer and one of the deadliest
thoracic tumours. Historically, chemotherapy consisting of either platinum plus etoposide or …

Background Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and
small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a …